Researchers looked specifically at head-to-head randomized clinical trials of next-in-class cancer drugs against existing agents in the same class. Less than one-quarter of next-in-class cancer drugs ...

Retrospective study finds link between blockbuster drugs and longer survival ...

In an analysis of all FDA approvals for anticancer drugs from 2009 to 2020, only about 29% of next-in-class drugs were evaluated in head-to-head randomized clinical trials (RCTs) against their ...

The FDA's cancer advisors will discuss AstraZeneca’s application for the oral SERD camizestrant in breast cancer and the AKT ...

Thanks to modern therapies, a cancer diagnosis is no longer an automatic death sentence. But many patients still suffer from ...

Oct 24 (Reuters) - A newer class of cancer drugs can delay disease progression or extend survival for breast cancer patients, multiple teams of researchers reported at a major European oncology ...

Cipla USA has recalled over 400 cartons of Nilotinib Capsules used to treat blood cancers after they failed to meet specifications, according to the U.S. Food and Drug Administration, which classified ...

In 22.2% of trials, there was a survival benefit with the next-in-class agent. Less than one-quarter of next-in-class cancer drugs demonstrated a survival benefit over existing in-class agents in head ...